Vol 71, No 1 (2020)
Clinical vignette
Published online: 2019-09-30

open access

Page views 3098
Article views/downloads 817
Get Citation

Connect on Social Media

Connect on Social Media

Worsening of unrecognized tumour-induced osteomalacia with inadvertent use of recombinant human parathyroid hormone

Rimesh Pal1, Kanhaiya Agrawal1, Setu Gupta2, Anil Bhansali1, Arunanshu Behera3, Sanjay Kumar Bhadada1
Pubmed: 31566250
Endokrynol Pol 2020;71(1):102-103.


Not required for Clinical Vignette.

Article available in PDF format

View PDF Download PDF file


  1. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007; 18(6): 1637–1647.
  2. Pal R, Bhadada SK, Shingare A, et al. Tumor-induced osteomalacia: experience from three tertiary care centres In India. Endocr Connect. 2019 [Epub ahead of print].
  3. Minisola S, Peacock M, Fukumoto S, et al. Tumour-induced osteomalacia. Nat Rev Dis Primers. 2017; 3: 17044.
  4. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19(3): 429–435.
  5. Blau JE, Collins MT. The PTH-Vitamin D-FGF23 axis. Rev Endocr Metab Disord. 2015; 16(2): 165–174.
  6. Lanske B, Razzaque MS. Molecular interactions of FGF23 and PTH in phosphate regulation. Kidney Int. 2014; 86(6): 1072–1074.
  7. Hajime M, Okada Y, Mori H, et al. A case of teriparatide-induced severe hypophosphatemia and hypercalcemia. J Bone Miner Metab. 2014; 32(5): 601–604.